ABCL:NSD-Abcellera Biologics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 9.43

Change

+0.21 (+2.28)%

Market Cap

USD 2.69B

Volume

1.69M

Avg Analyst Target

USD 29.25 (+210.18%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

ABCL Stock Forecast & Price:
Based on the Abcellera Biologics Inc stock forecasts from 3 analysts, the average analyst target price for Abcellera Biologics Inc is USD 29.25 over the next 12 months. Abcellera Biologics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Abcellera Biologics Inc is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Abcellera Biologics Inc’s stock price was USD 9.43. Abcellera Biologics Inc’s stock price has changed by -8.36% over the past week, -16.25% over the past month and -55.07% over the last year.

About Abcellera Biologics Inc (ABCL:NSD)

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, th ...Read More

Company Website : https://www.abcellera.com

Address : 2215 Yukon Street, Vancouver, BC, Canada, V5Y 0A1

Employees : 450

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 20.30

Short Ratio : 9.01

52 Week Low : 5.42

Shorted Shares : 21,620,810

200 Day Moving Average : 10.02

Shorted Shares Previous Month : 20,054,613

50 Day Moving Average : 11.06

Shares Held By Insiders : 28.85%

Short Percentage : 13.18%

Shares Held by Institutions : 47.51%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+8.91 (+1.30%)

 USD74.83B 13.56 10.63
VRTX Vertex Pharmaceuticals Inc

+7.96 (+2.88%)

 USD72.69B 23.18 15.56
MRNA Moderna Inc

+2.54 (+2.12%)

 USD48.37B 3.83 2.59
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

+2.65 (+2.08%)

 USD31.55B 2.99 1.31
RPRX Royalty Pharma Plc

+0.35 (+0.88%)

 USD27.26B 39.16 19.50
SGEN Seagen Inc

+0.08 (+0.06%)

 USD24.95B 55.02 -36.47
ALNY Alnylam Pharmaceuticals Inc

+5.22 (+2.64%)

 USD23.69B N/A -31.40
GMAB Genmab AS

+0.30 (+0.95%)

 USD21.80B 40.29 3.47
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ABCL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -34.06% 70% C- 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.06% 70% C- 44% F
Trailing 12 Months  
Capital Gain -51.91% 66% D 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.91% 66% D 35% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -26.65% 22% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.65% 22% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 32.42% 75% C 52% F
Risk Adjusted Return -82.20% 18% F 6% F
Market Capitalization 2.69B 94% A 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 16.26 31% F 51% F
Price/Book Ratio 2.16 43% F 36% F
Price / Cash Flow Ratio 998.20 0% N/A 1% F
EV/EBITDA 5.30 5% F 33% F
Management Effectiveness  
Return on Equity 18.38% 96% A 86% B
Return on Invested Capital -16.56% 82% B- 38% F
Return on Assets 12.29% 98% A+ 96% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 9.01 23% F 13% F
Short Percent 13.18% 12% F 11% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment
Stock Target Advisor

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.